Sandoz free to launch Humira biosimilar in Europe following AbbVie deal

The European patent on Humira, the world’s biggest selling drug, will expire on Tuesday and a host of companies have cheaper biosimilars ready to compete.

However, Sandoz will have to wait until the end of September 2023 to launch in the US, because of the legal protection AbbVie secured in the territory, under the terms of the agreement.